Literature DB >> 29203183

The IL-1 family of cytokines. Do they have a role in scleroderma fibrosis?

Carol M Artlett1.   

Abstract

Systemic sclerosis is a profibrotic autoimmune disease mediated by the dysregulation in collagen synthesis, leading to the increased deposition of collagens, primarily type I and III, and the deposition of other extracellular matrix proteins in the skin and internal organs, in a mechanism that is thought to be an over active wound healing process. These patients experience significant morbidity and the mortality rate in this disease is high. Indeed, scleroderma is the most deadly of diseases in the autoimmune spectrum. Recent evidence has placed the assembly and chronic activation of the inflammasome as a central driver of fibrosis. Once assembled, the inflammasome is a large protein complex that regulates the release of IL-1, IL-18, and IL-33, which are thought to play a role in the fibrotic response. IL-36 also belongs to the IL-1 family of cytokines and is a new comer to this field of research. Recent analyses of the IL-1 family of cytokines have demonstrated that many of them play a role in skin inflammation and fibrosis and their corresponding antagonists (IL-1RA and IL-36RA) can abrogate this pathology. Understanding how these cytokines are regulated and how they contribute to fibrosis will be important to understanding this pathology and may shed light in new areas for therapeutic development.
Copyright © 2017 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fibrosis; IL-1; IL-18; IL-33; IL-36; Systemic sclerosis

Mesh:

Substances:

Year:  2017        PMID: 29203183     DOI: 10.1016/j.imlet.2017.11.012

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  7 in total

Review 1.  IL-33/ST2 Axis in Organ Fibrosis.

Authors:  Ourania S Kotsiou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

Review 2.  Drugs in phase I and phase II clinical trials for systemic sclerosis.

Authors:  Melody P Chung; Lorinda Chung
Journal:  Expert Opin Investig Drugs       Date:  2020-03-25       Impact factor: 6.206

Review 3.  IL-36 in chronic inflammation and fibrosis - bridging the gap?

Authors:  Michael Elias; Shuai Zhao; Hongnga T Le; Jie Wang; Markus F Neurath; Clemens Neufert; Claudio Fiocchi; Florian Rieder
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

Review 4.  Inflammasome as an Effective Platform for Fibrosis Therapy.

Authors:  Ting-Ting Chen; Feng Xiao; Nan Li; Shan Shan; Meng Qi; Zi-Ying Wang; Sheng-Nan Zhang; Wei Wei; Wu-Yi Sun
Journal:  J Inflamm Res       Date:  2021-04-20

Review 5.  Critical role of inflammatory mast cell in fibrosis: Potential therapeutic effect of IL-37.

Authors:  P Conti; Al Caraffa; F Mastrangelo; L Tettamanti; G Ronconi; I Frydas; S K Kritas; T C Theoharides
Journal:  Cell Prolif       Date:  2018-07-30       Impact factor: 8.755

Review 6.  Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis.

Authors:  Chang-Youh Tsai; Song-Chou Hsieh; Tsai-Hung Wu; Ko-Jen Li; Chieh-Yu Shen; Hsien-Tzung Liao; Cheng-Han Wu; Yu-Min Kuo; Cheng-Shiun Lu; Chia-Li Yu
Journal:  Int J Mol Sci       Date:  2020-04-27       Impact factor: 5.923

7.  IL-13 and IL-33 Serum Levels Are Increased in Systemic Sclerosis Patients With Interstitial Lung Disease.

Authors:  Antonio Giovanni Versace; Alessandra Bitto; Carmelo Ioppolo; Caterina Oriana Aragona; Daniela La Rosa; William Neal Roberts; Tommaso D'Angelo; Antonella Cinquegrani; Santa Cirmi; Natasha Irrera; Michele Navarra; Salvatore Corrao; Sebastiano Gangemi; Gianluca Bagnato
Journal:  Front Med (Lausanne)       Date:  2022-02-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.